Good day. Thank you for standing by. Welcome to the InnovAge Q3 2023 Earnings Conference Call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there'll be a question-and-answer session. To ask a question during the session, you'll need to press star one one on your telephone. You will hear an automated message advising your hand is raised. To withdraw your question, please press star one one again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Ryan Kubota, Director of Investor Relations. Please go ahead. Thank you, operator. Good afternoon, thank you all for joining the InnovAge Fiscal 2023 Q3 earnings call. With me today is Patrick Blair, President and CEO, and Barb Gutierrez, CFO. Dr. Rich Feifer, Chief Medical Officer, will also be joining the Q&A portion of the call. Today, after the market close, we issued a press release containing detailed information on our quarterly results. You may access the release on our company website, innovage.com. For those listening to the rebroadcast of this call, we remind you that the remarks made herein are as of today, Tuesday, May 9th, 2023, and have not been updated subsequent to this call. During our call, we will refer to certain non-GAAP measures. A reconciliation of these measures to the most directly comparable GAAP measures can be found in our fiscal Q3 2023 earnings press release, which is posted on the investor relations section of our website. We will also be making forward-looking statements, including statements related to our remediation measures, including scaling our capabilities as a provider, expanding our payer capabilities, and strengthening our enterprise functions, future growth prospects, the status of current and future regulatory actions, Florida de novo centers, and other expectations. Listeners are cautioned that all of our forward-looking statements involve certain assumptions and are inherently subject to risks and uncertainties that can cause our actual results to differ materially from our current expectations. We advise listeners to review the risk factors discussed in our Form 10-K annual report for fiscal year 2022 and our subsequent reports filed with the SEC, including our quarterly report on Form 10-Q for our fiscal Q3 2023. After the completion of our prepared remarks, we'll open the call for questions. I will now turn the call over to our President and CEO, Patrick Blair. Patrick. Thank you, Ryan, and good afternoon, everyone. I want to start by expressing my ongoing gratitude to our InnovAge colleagues, participants, government partners, and the investor community who support our organization. Let me begin by humbly sharing what the InnovAge team has accomplished in the last 19 months. We resolved audit deficiencies across half our centers while simultaneously building trust with our federal and state regulatory partners. We closed mission-critical people, process, and technology gaps identified as causes of the audit deficiencies and strengthened our operations. We implemented Epic at half our centers and have a path to being fully operational at every center by year-end. We made a healthy down payment on a set of essential payer capabilities that we believe will better position us to manage medical costs going forward. We reversed the negative trends of financial performance and are now in a phase of growth and margin recapture. These accomplishments were made possible by the efforts of literally thousands of InnovAge employees. Thank you all for what you have done to make this happen. As many of you know, one week ago, we reached an important milestone in our transformation by being released from enrollment sanctions in Sacramento, California, by the Department of Health Care Services, which was the last remaining sanction. With the support of CMS in the state of California and our unwavering commitment to sustainable improvement, we're now able to enroll new participants across all 17 InnovAge centers, as well as responsibly pursue opportunities in new markets. This moment can be viewed as the end of one chapter and the beginning of a new one. Our centers have been focused on closing compliance gaps and building the infrastructure, business processes, talent, and culture to consistently achieve operational excellence. The chapter in front of us will build on the shoulders of the last and will concentrate on aspiring to deliver best-in-class quality and participant satisfaction, which we believe will result in consistent, responsible, profitable growth. The hard work of performance improvement begins now. On the leadership front, we continue to augment the organization with additional high-impact talent, most notably and recently, the addition of our Chief Operating Officer, Chris Bent. Chris has decades of multi-site care delivery operations experience. Her experience will be essential to not only building on the team's great work over the last 19 months, but also to creating a more scalable infrastructure to support the significant opportunities ahead. We also saw a few encouraging operational milestones this quarter. Perhaps most notably, census is now increasing on a sequential basis, albeit modestly, for the first time since November 2021. Our financial trends are improving as we reported adjusted EBITDA of $3.8 million this quarter. Barb will spend some time dimensionalizing both the results and the underlying trends which are expected to impact future quarters. As I noted briefly, we're midway through implementing our industry-leading PACE-specific version of Epic in all of our centers. That all said, I don't believe our progress will be a straight line up and to the right. There will be inevitable surprises ahead, and gearing up the organization for growth will take some time. We also need to acknowledge that our risk mix has been negatively impacted primarily by the inability to enroll new participants in our largest market until recently. This dynamic can understandably take significant time to rebalance itself. Our focus and progress trajectory remain consistent with what we shared last quarter. My comments today will encompass a regulatory update, progress in our focus areas, and perspectives on the quarterly financial performance. Let me begin the regulatory update by expressing my sincere appreciation to our government partners for their confidence in us and for their ongoing partnership. As I mentioned last quarter, we are committed to remaining fully vigilant to ensure that a rigorous compliance focus is bedrock to InnovAge's way of doing business. As I just noted and discussed in our May first press release, we have been released from enrollment sanctions in Sacramento by the California Department of Health Care Services and can begin enrolling again. To be sure this is good news for our ability to pursue our broader desired footprint in California. Sacramento currently has only a small census of about 130 participants today, we believe it's an attractive market and has the potential to drive meaningful organic growth, especially with our JV partners, Adventist Health and Eskaton. In the state of Florida, we're also excited to share that we resumed the administrative process to open centers in Tampa and Orlando. Recall we began construction on these facilities in mid-2021 and intentionally hit pause to focus on remediating the Colorado and California audit findings in 2022. We aspire for these 2 centers to meet our high expectations for participant experience. Each center is approximately 35,000 sq ft, has a potential mature census of 1,300 participants, and incorporates numerous historical best practices to optimize care delivery. The opening of these 2 centers is expected to expand our total census capacity by over 20%. As I've noted in the past, the administrative process will likely take months. We're holding ourselves accountable to execute everything within our control to get them operational as quickly as possible, which we anticipate will be later this calendar year. You can be sure that our commitments to CMS related to quality, compliance, and operational excellence extend to our Florida centers as well. I also wanted to touch on the ongoing corrective action plan in Colorado. Our partners at CMS in the state have continued to hold us to a very high standard post-sanction, appropriately so. While we are aligned, I want to acknowledge that the overall time, effort, and scope of the post-sanction monitoring continues to be significant. As a result, these efforts are expected to create a modest but ongoing headwind to our local staffing costs and the rate of staffing ratio improvement for the remainder of the calendar year. Consistent with my comments over the past few quarters, our near-term priorities remain straightforward. We need to ensure a highly compliant and operationally effective business while executing a responsible growth strategy. Our key objectives have also not changed. We want to increase our same-center and de novo enrollment growth rate, increase our revenue per participant through more effective state rate-setting discussions to ensure rates are fair and actuarially sound, strengthen our payer capabilities to better manage unnecessary utilization and provider costs, run our center operations more efficiently and effectively, which enables our staff to focus on what matters most, the health and well-being of our participants. Enhance discipline at the corporate level to better leverage our fixed cost base. On the growth front, we have been focusing on adding the right talent, ensuring the team has the right tools for the job, expanding our referral channels, and improving forecasting effectiveness. In the last few months, we've seen more lead volume than any other time across both field and digital channels. We're focused now on qualifying these leads and on enrollment conversion. This is a team effort between us and our state partners who ultimately process the enrollments. We continue to challenge ourselves to improve each dimension of the enrollment funnel to be more productive, consistent, and predictive each month. In Colorado specifically, I wanted to spend a minute detailing the shape of the anticipated enrollment over the coming months. Recall we were released from sanctions at the end of January. We enrolled our 1st group of new participants on the 1st available date of March 1st, consistent with required PACE enrollment processing timelines. At the same time, we are actively developing a pipeline of potential PACE participants who have expressed an interest in enrolling. We are facilitating the necessary third-party approvals to satisfy Medicare and/or Medicaid requirements to join PACE, which can take on average between 60 and 90 days. Critically, we have been intentional within our centers to gradually reintroduce new enrollments, as it's a muscle and mindset we have not flexed in over a year. It's been a deliberate ramp-up in Colorado over the last few months, and we anticipate it will take at least another quarter to have confidence in our enrollment run rate. In addition to the organic focus, we're pleased with the level of activity in the market for tuck-in acquisitions and new partnership opportunities. That said, we're resolved to let nothing distract us from our compliance focus in filling existing center capacity. We will continue to be opportunistic and will focus on organizations that share our commitment to quality and participant-centric care. Last quarter, I mentioned the importance of using the rate-setting process both on and off cycle as an opportunity to work closely with states to ensure we receive actuarially sound rate adjustments that properly consider the acuity and underlying risk of our participants, as well as the inflationary factors inherent in our business. Primarily as a byproduct of sanctions, our risk mix now comprises a disproportionate share of participants with greater healthcare and supportive housing needs, like assisted living. As we have discussed before, our population was also disproportionately impacted by COVID. Now more than ever, it is incumbent on us to empirically prove out our medical cost experience to our state partners, which we believe to be higher today than is reflected in the historical data that can be used to set future rates. To support our work here, we recently hired Randy Brock as Senior Vice President of Medical Economics. Randy brings decades of experience from Anthem and Amerigroup working to ensure rates for Medicaid managed long-term care and dual-eligible programs reflect the true cost of serving these high-needs populations. Barb will provide an update on the current rate-setting activity and timing of when new rates will go into effect. Our portfolio of clinical initiatives, or CBIs, continues to progress. We now have a strong perimeter around the near-term opportunities and accountable leaders to drive these initiatives forward. However, as I've mentioned in the past, these will be dials, not switches, and we do not expect the financial impact of these initiatives to materially contribute to our financial results until next fiscal year. I would also note that the current portfolio of initiatives is primarily prophylactic and that we're looking for improvement to offset currently elevated costs until we have added enough new participant growth to balance the risk pool. As an example, our focus on resource management led to the identification of short-stay skilled nursing facility, or SNF, utilization as a top priority. We launched an initiative to determine where and when this service is clinically needed for participants and to find alternative care settings for times when it is not necessary. As a result of these efforts, we have achieved a meaningful reduction in monthly short-stay SNF utilization over the last 12 months. Furthermore, for those participants needing a SNF for short-stay medical care, our average monthly short-stay SNF days has dropped approximately 25% over the fiscal year to date. This is great progress on an important cost driver, but we have other cost categories, like inpatient admissions, that are stubbornly higher than our current expectations. In addition to our initiatives discussed last quarter, we're kicking off a new effort focused on lowering external provider unit costs when out of line with benchmarks. We'll also be streamlining our assisted living facility network to match our capacity to provide compliance oversight and to better meet the needs of our census. We believe this initiative will help lower our external provider costs and improve the participant experience. Turning to center operations. As I mentioned earlier, we have 9 of our 17 centers live on Epic, with the remainder scheduled for the first half of fiscal year 2024. We've made the decision to pull forward the Colorado market go live to early fiscal year 2024. Pulling forward the 6 centers in Colorado earlier than originally anticipated will likely create modest G&A headwinds in fiscal year 2024, but we believe the expected benefit will more than offset the incremental investment. Though it takes many months to achieve full adoption and the expected benefits of a new system, we're encouraged by the operational efficiencies that are emerging and the positive feedback our administrative and clinical teams are sharing. We expect the Epic investment to be a powerful enabler to drive better compliance, productivity, and clinical staff satisfaction. We also continue to make meaningful progress implementing our new Triad operating model, which focuses on the partnership among the center directors, nursing directors, and medical directors at the center, regional, and national levels. The Triad model is predicated on driving better participant care, making faster operating decisions, and improving center-level contribution margin. We're starting to see the impact of forming this tight-knit team with aligned incentives and joint accountability. Regarding corporate costs, we continue to maintain discipline to hold corporate staffing costs constant as we grow back into our fixed cost base. The hiring controls we put in place six months ago have helped us better match our hiring pace and volume to our financial targets. We continue to focus on actions to ensure our G&A relative to revenue is aligned while using savings as a funding mechanism for tools and technology that will improve efficiency and effectiveness. We believe there is a virtuous cycle behind these efforts in which our employees can be more productive, satisfied, and scalable. We've also looked beyond the P&L and found opportunities to optimize our working capital, which we believe will drive approximately $10 million of benefit once fully implemented by the start of fiscal year 2024. Turning to financial performance, we reported revenue of $172.5 million, a sequential improvement of approximately 3% compared to last quarter. We ended the quarter serving approximately 6,310 participants. For the quarter, we reported center-level contribution margin of $28.8 million and a corresponding center-level contribution margin ratio of 16.7% compared to Q2 fiscal year 2023 center-level contribution margin of $22.6 million, an increase of $6.2 million and margin improvement of 320 basis points. The quarter overall demonstrated incremental progress in our core focus areas. However, as I mentioned at the outset, it remains too early to take the results of the quarter and extrapolate them into the future. We had the benefit of a few one-time tailwinds, which Barb will discuss, and we continue to face medical cost pressures from our deconditioned participant risk mix, which will take some time to normalize. To help contextualize that point, our consolidated RAF score as of March 31st was 2.53, which is up approximately 5% relative to our year-to-date average. To accelerate rebalancing of our risk pool, we will continue to focus on employing the slack capacity at our existing centers, particularly in the Colorado market, where resilient enrollment growth will drive better labor utilization at our centers and help rebalance our mix of new and tenured participants, which should improve participant expense PMPMs. In closing, the team's collective dedication to our participants and hard work through this last chapter, along with numerous investments in new processes, is beginning to unlock the full potential of the organization. I greatly appreciate their tireless efforts and continued commitment and the ongoing support of our valued government partners. We look forward to continuing to demonstrate incremental improvement quarter-over-quarter in each of our focus areas, and are seeking additional catalysts to deliver breakthrough impact and value to the organization over time. I know I speak for the entire organization that we are thrilled to be returning to our core mission of expanding PACE to the many deserving, underserved seniors across the country. Now I will turn it over to Barb. Thank you, Patrick. Good afternoon, everyone. Today, I will provide some highlights from our Q3 fiscal year 2023 performance and some insights into the trends we are seeing through the end of the fiscal year. As with our previous earnings calls, I will refer to sequential comparisons relative to the Q2 in order to provide a more meaningful picture of our performance. At the end of the quarter, we served approximately 6,310 participants. Compared to the prior year, this represents an ending census decline of 7.1% and a 2.2% decline compared to the Q2 of fiscal year 2023. We reported approximately 19,060 member months for the Q3, a 7.6% decrease over the prior year and a decrease of 2.1% over the Q2 of fiscal 2023. The enrollment freeze in Colorado had the greatest impact on member months and census compared to the Q3 of fiscal 2022 and sequentially. We are pleased that we are now ramping up the enrollment of new participants following our release from sanctions in Colorado in late January and have begun to ramp up the enrollment process in Sacramento as well, following our release from sanctions on May 1st. The timing of our Colorado sanction release in late January, coupled with the typical enrollment processing timeline of 30-60 days, as well as the enrollment cycle for new participants starting at the beginning of each month, translate into limited enrollment during the quarter. However, we are steadily gaining momentum as the process continues to mature and we anticipate returning to a more normalized growth run rate in the next few quarters. We also expect Sacramento to follow a similar timeline with respect to the ramp- up of new participant enrollment as we reengage with the local community and connect with potential participants. Additionally, during the quarter, we consolidated our Germantown center in Pennsylvania and moved existing participants and staff to our Allegheny and Henry Avenue centers. The move, which included prior approval from CMS and the state, as well as participants and employee input, transitioned approximately 170 participants to newer, larger centers with additional amenities less than 5 miles away. As a result, total center count has decreased from 18 to 17. Total revenue decreased by 2.7% to $172.5 million compared to the Q3 of fiscal year 2022, principally due to the sanctions, though slightly offset by the ramp- up of new enrollments in Colorado. The decrease was also partially offset by the annual increase in Medicaid and Medicare rates, which are net of the full reinstatement of sequestration in July 2022. Additionally, our risk scores increased quarter-over-quarter by 9.5%, reflecting the overall increased acuity of our participants in our risk pool. Compared to the Q2, revenue increased 3%, primarily as a result of an increase in Medicare rates. This increase was partially offset by lower member months associated with sanctions, despite the ramp- up of new enrollments in Colorado. We incurred $89.8 million of external provider costs during the quarter, a 13% decrease compared to the prior year. The decrease was driven by lower member months, coupled with a 5.9% decrease in cost per participant. The cost per participant decrease was primarily due to lower inpatient cost per admit as a result of the Omicron spike in the prior year and lower short stay skilled nursing utilization, as Patrick referenced in his prepared remarks. The decrease is partially offset by an increase in assisted living and permanent nursing facility utilization, as well as unit cost. Sequentially, external provider costs decreased by 4%, primarily as a result of lower census and lower per member per month pharmacy expense due to higher than anticipated rebates, partially offset by an increase in inpatient utilization and cost per admit, which is typically elevated during the winter months as a result of seasonality. Cost of care, excluding depreciation and amortization of $53.9 million, was 17% higher compared to the prior year. Similar to our experience last quarter, the primary cost drivers include the following items. One, salaries, wages, and benefits, which accounts for approximately 80% of the total variance, increased due to higher headcount as a result of filling key vacancies, higher wage rates, and increased labor costs associated with ongoing audit remediation and compliance efforts. Two, third party audit and compliance support as we work through the audits and proactively performed self-audits in our non-sanctioned markets. Three, fleet and contract transportation driven by higher average daily attendance in our centers, an increase in external appointments and higher fuel costs. Four, increased building maintenance and security costs associated with growth in average daily attendance. Cost of care increased 5% over the Q2 of fiscal 2023, primarily due to increased wage rates and headcount, coupled with an increase in building maintenance. Center level contribution margin, which we define as total revenue less external provider costs and cost of care, excluding depreciation and amortization, was $28.8 million for the Q3, compared to $28 million in the prior year and $22.6 million in the Q2 of fiscal 2023. As a percentage of revenue, center level contribution margin for the quarter was 16.7%, representing a 90 basis point improvement over the prior year and a 320 basis point improvement over the prior quarter. Sales and marketing expense was $5.3 million, an $800,000 decrease compared to the prior year. The decrease was mainly due to lower sales headcount as a result of the sanctions, partially offset by one-time costs related to organizational realignment completed in the Q3 of 2022. Compared to the Q2 of fiscal year 2023, sales and marketing expense increased by $1.5 million, primarily due to increased marketing spend and sales headcount following the Colorado sanction lift and the addition of traditional media in all non-sanctioned markets. Corporate general and administrative expense was $27.6 million, a $3 million increase compared to the prior year. This was primarily due to an increase in headcount to support compliance and bolster organizational capabilities, an increase in third-party legal spend, and an increase in software license and maintenance expenses, including Epic. These costs were partially offset by a reduction in bad debt expense and lower consulting expense associated with laying the groundwork for strengthening organizational capabilities. Sequentially, corporate general and administrative expense decreased $1.2 million due to lower third-party legal expense, reduction in contract services associated with Epic implementation in our centers in the East region, continued tapering of certain third-party consultant expenses associated with improving organizational capabilities, and a reduction in bad debt expense. These decreases were partially offset by an increase in headcount and employee-related costs and an increase in software license and maintenance expenses. Net loss was $7.3 million compared to net loss of $3.2 million in the Q3 of fiscal 2022. We reported a net loss per share for the fiscal Q3 of $0.05 on both a basic and diluted basis. Our weighted average share count was 135,601,327 shares for the Q3 on both a basic and fully diluted basis. Adjusted EBITDA, which we calculate by adding interest, taxes, depreciation, and amortization, one-time adjustments for transaction and offering related costs, and other non-recurring or exceptional costs to net income, was $3.8 million compared to $1.9 million in the Q3 of fiscal year 2022 and -$2 million in the Q2 of fiscal year 2023. Our adjusted EBITDA margin was 2.2% for the Q3 compared to 1.1% for the Q3 of fiscal year 2022 and -1.2% for the Q2 of fiscal year 2023. The sequential quarter-over-quarter improvement in adjusted EBITDA and adjusted EBITDA margin is primarily a function of increased Medicare capitation rates, improvement in external provider cost per member per month resulting from pharmacy rebates, and lower G&A, partially offset by increased cost of care and increased sales and marketing. We do not add back any losses incurred in connection with our de novo centers in the calculation of adjusted EBITDA. De novo center losses, which we define as net losses related to pre-opening and start-up ramp through the first 24 months of de novo operations, were approximately $880,000 for the Q3, primarily related to centers in Florida. Turning to our balance sheet, we ended the quarter with $121.7 million in cash and cash equivalents, plus $45.8 million in short-term investments. We had $89.1 million in total debt on the balance sheet, representing debt under our senior secured term loan, plus finance lease obligations and other commitments. For the Q3, we recorded cash flow from operations of $29.1 million, inclusive of $26 million of deferred revenue, and we had $4.7 million of capital expenditures. As Patrick indicated, in this quarter, we benefited from certain one-time or timing-related tailwinds, which cannot be extrapolated for the remainder of fiscal 2023 or into fiscal 2024. Over the remainder of the fiscal year and into the next fiscal year, trends will evolve related to enrollment growth, post-sanction cost structure, and the impact of CBIs. With that said, I will provide some additional visibility around the following trends we are seeing. Regarding census, while our focus remains on ramping up our enrollment efforts in Colorado and Sacramento, I want to briefly provide some additional detail on the impact of Medicaid redetermination as a result of the end of the public health emergency. The nature of our population and the complexity of the Medicaid services our participants receive result in a comprehensive financial qualification as compared to the more traditional Medicaid-only population. Additionally, we completed annual Medicaid redetermination throughout the public health emergency with a dedicated team to support these efforts. Our process enables us to provide a high degree of service to participants to monitor eligibility, assist with the redetermination process, address potential issues with eligibility in real time, and track future renewal dates, which we believe will result in minimal pre-COVID levels of financial disenrollments. Regarding revenue, as we said last quarter, effective January 1st, we experienced a low double-digit Medicare rate increase associated with an annual increase in county rates coupled with an increase in risk scores. This positive outcome was tempered by a low single-digit Medicaid rate decrease from the State of California, resulting in a net mid-single digit rate increase in the aggregate. To appropriately optimize our opportunity to be accurately compensated for the full risk profile of our participants, we are building out our internal competencies around revenue participant and around the rate-setting process to more actively engage with our regulators. Most of our states, including Colorado, are on a July 1st fiscal year. We plan to utilize these augmented capabilities during the rate-setting cycle currently in progress. Some thoughts on cost of care, external provider costs, and overall center level margins. In the midterm, we continue to believe that we can obtain margins similar to what we experienced before the sanctions. Although the composition of our center level costs may look slightly different. The investments that we have made, particularly in staff-related costs, have elevated our cost of care expense compared to historical levels. We are driving value through other revenue and cost focus areas, such as our payer initiatives and CVIs to bend the curve and deliver margin over time. It will take multiple quarters to return to more robust margins, our focus remains on the key drivers, specifically, accelerating census growth, which also serves to rebalance the participant risk pool as well as to unlock staffing capacity, optimizing revenue per participant through diligence on the accuracy of risk scores, and executing on Clinical Value Initiatives to improve participant care and reduce unnecessary costs, all of which we expect will drive a meaningful improvement in our margin profile. In closing, we are excited to be turning a page as we begin to focus on growth and expansion once again. We remain extremely proud of the hard work and accomplishments that have brought us to this point, and we look forward to expanding access to PACE in the future to the many seniors who could benefit from the program. Operator, that concludes our prepared remarks. Please open the call for questions. Thank you. One moment. As a reminder, to ask a question, please press star one one on your telephone and wait for your name to be announced. To withdraw your question, please press star one one again. Please stand by while we compile the Q&A roster. One moment for our first question. Our first question comes from Lisa Gill from JP Morgan. Your line is now open. Thanks very much, and thanks for taking the question. Congratulations on getting everything back up online. Barb, let me just first start with you've given us a lot of information, but really not quantifying anything. I'm just curious as to when you think you'll be in a position to maybe give us some incremental numbers and when you'll bring back guidance would be my first kind of overarching question? Secondly, maybe if you can just also help us to think about the speed at which you'll be able to backfill your capacity in your center, like how quickly can you start to ramp back up again? Hey, Lisa, it's Patrick. Let me just kind of jump in on the guidance question, and then I'll hand it off to Barb to fill in anything I miss. You know, clearly it's our intention to provide guidance on a go-forward basis. I think the question is, you know, we're not ready today to say exactly, you know, when that will be. You know, we do believe it's appropriate, you know, to take a bit of a conservative posture on the timing for that. There's sort of a few reasons that, you know, I think we hit in the script, but just sort of come to mind. For 1, it's, you know, it's still a pretty dynamic business as we just exit, you know, the sanctions and begin to grow again in our largest market, which has really had, you know, a pretty significant impact on the company. And then, you know, there's still a number of drivers that we'd just like a bit more clarity on before providing guidance. I think 1, you know, which we touched on is we're making great progress in Florida, but it's still a question of exactly when is Florida gonna start, you know, generating revenue. And I think that's something we wanna have a better read on. You know, Barb mentioned. You know, our participant mix. And there's still a question, just, you know, how quickly is that risk pool going to rebalance and normalize as a result of the growth? We're trying to get, you know, as much of a read on that as quickly as we can. You know, then we talk about the staffing ratios in Colorado. You know, it's a big market. There's a lot of people. You know, the growth rate in Colorado following a year of not growing can have real impact on those ratios. We have to understand that. You know, I also mentioned, I think, my prepared remarks, just this notion of the post-monitoring oversight by the regulators continues to be pretty resource- intensive. You know, we're gonna work hard over the next few months to dial all these things in, but I don't think we're ready to say today exactly what date guidance will be reinstituted, but we're very committed to getting there as quickly as possible. Barb, anything you'd add? No. Maybe her second question. Yeah. Yeah, glad to answer any other specific questions, Lisa. That was helpful. Now just the second one was just really around the ramp. Now that, you know, Sacramento is back online, how quickly can you start to get new patients into your facilities? Good question. We, you know, the sanctions were lifted in Colorado, I think it was January 23rd. It took us a bit of time to ramp up the enrollment process. You know, our March enrollment was, I'll say, good given the time that we had, but it was limited as you if you compare that to sort of historical run rates. In April and May, we've had nice momentum, so I think we're tracking well with our internal targets, and we've got a solid pipeline of prospects who are interested in joining PACE. I think we're probably seeing a few more that need to get their Medicaid coverage, which can take 60, 90 days, but, you know, that's not everyone in the pipeline. We still have some folks that are ready to enroll now. You know, I expect that we're gonna get back to our historical run rate in Colorado in the Q1 of the new fiscal year. You know, we're certainly challenging ourselves to pull that forward and improve productivity in every market. I think, you know, if I sort of zoom out and think about the full business, you know, I would say, you know, excluding de novos, we expect to be back at historical net, you know, monthly enrollment levels in the Q1 2024 of our fiscal year. We're certainly challenging ourselves to do it faster, but right now that feels like the right trajectory to get back to those historical levels. Okay, great. Thanks for the comments. Anne, thank you. If you would like to ask a question, that is star one one. Again, if you would like to ask a question, that is star one one. One moment for our next question. Our next question comes from Matt Larew from William Blair. Hi, this is actually Madeline on for Matt. I was just wondering, obviously small sample size right now, but have you seen anything you can say about patient acuity trends in the population that you're enrolling in Colorado so far, or at like risk score trends there? I think it's a bit too early for that. We're just a couple of months in here, and it takes a little time for the participant profile and the claims history to build. It is just a little early to answer that. Got it. Just thinking about the enrollment process in general, and I think you mentioned that, you know, you're sort of learning to exercise that muscle again. Anything that you've learned from the Colorado process that you think would make Sacramento more smooth or make it easier to start on adding new patients in Sacramento? You know, I think one of the things that, you know, we focused on a lot is really spending time to build our referral engagement channels. We have a variety of, you know, community-based organizations that we work with, you know, everything from sort of benefits counseling to faith-based organization to food pantries, foster care, housing alternatives. I mean, the list goes on. You know, I think we did a really nice job of building, you know, a game plan in Colorado for each of those channels, and we've gotten a jump-start on that in Sacramento. I think, you know, just getting a great view of the landscape is really important. You know, I also think that Sacramento is just one center, so it's a lot less complex to sort of ramp up than the whole, you know, our largest market has been in Colorado. I think we got our first enrollment already in Sacramento, so I think we're feeling, you know, good about the ramp-up there, and we think it'll kind of follow the shape of Colorado in terms of build-out. Great. Thank you. Then just one more for me. Thinking about the Florida centers, I think you had mentioned last quarter that you were waiting on some licensures, like adult daycare license and things like that. Is that still sort of what's holding up the process, or can you talk a little bit about what more there is to do in Florida from a regulatory standpoint? Sure, sure. First thing that I would say is we're very pleased with the progress. We've had great engagement with the state. I think we're, you know, sort of blessed to have them, to have the state, you know, so interested in us entering the market as a, as a PACE provider. As soon as the sanctions were lifted in Colorado, we resumed the application process. We're pleased with the adult daycare application. It's, you know, that's what we're executing on right now is the adult daycare application. There's the state readiness review and a CMS review, and then there's the three-way agreement. Overall, I think we're tracking nicely to get this done before the end of the calendar year. We're gonna do everything we can to that's in our control to pull that forward even earlier in the year if possible. Couldn't be more excited about Florida. Great. Thank you so much. Thank you for taking my question. You bet. Thank you. Bear with me one moment, please. One moment for our next question. Our next question comes from Jamie Perse from Goldman Sachs. Your line is now open. Hi, this is Nagee Ibong for Jamie Perse. Thanks for taking my question. I was just wondering about external provider costs. I mean, they were down this quarter, and I was just wondering if where do you expect it to trend going forward past this quarter in terms of as a%? Yeah, sure. Hi, it's Barbara. I'll take that question. You're right, the trend is down this quarter. You know, we did mention that in large part that was due to a pharmacy rebate that we received during the quarter. About two-thirds of that decrease relates to that. There is definitely we are seeing some improvement as it relates to some of our clinical value initiatives and other things we're focusing on. I think both Patrick and I, in our prepared remarks, for example, mentioned some efforts related to the short stay skilled nursing facility that we're seeing some nice trends. Embedded in that decrease are some nice trends related to the medical costs. For this quarter in particular, that was, you know, the bulk of it, two-thirds of it was related to the pharmacy rebate. Thank you. I am showing no further questions. I would now like to turn the call back over to Patrick Blair, President and CEO, for closing remarks. Well, thank you very much. I appreciate everyone who joined the call. We continue to believe that, you know, the company is on the right track, and we're excited about our future and excited about closing one chapter and beginning a new chapter. We look forward to the discussion on our incremental progress in another few months. Thank you for your time today. This concludes today's Conference Call. Thank you for participating. You may now disconnect.